GLAXF - GlaxoSmithKline plc

Other OTC - Other OTC Delayed price. Currency in USD
Show:
Balance sheet
Cash flow
Annual

Income statement

Currency in GBP. All numbers in thousands
Breakdown
ttm
31/12/2022
31/12/2021
31/12/2020
31/12/2019
Total revenue
29,324,000
29,324,000
34,114,000
34,099,000
33,754,000
Cost of revenue
9,554,000
9,554,000
11,603,000
11,704,000
11,863,000
Gross profit
19,770,000
19,770,000
22,511,000
22,395,000
21,891,000
Operating expenses
Research development
5,488,000
5,488,000
5,278,000
5,098,000
4,568,000
Selling general and administrative
8,372,000
8,372,000
10,975,000
11,456,000
11,402,000
Total operating expenses
13,041,000
13,337,000
16,310,000
14,612,000
14,930,000
Operating income or loss
6,729,000
6,433,000
6,201,000
7,783,000
6,961,000
Interest expense
826,000
879,000
784,000
892,000
912,000
Income before tax
5,628,000
5,628,000
5,442,000
6,968,000
6,221,000
Income tax expense
707,000
707,000
346,000
580,000
953,000
Income from continuing operations
4,921,000
4,921,000
5,096,000
6,388,000
5,268,000
Net income
14,956,000
14,956,000
4,385,000
5,749,000
4,645,000
Net income available to common shareholders
14,956,000
14,956,000
4,385,000
5,749,000
4,645,000
Basic EPS
-
3.71
1.10
1.44
1.17
Diluted EPS
-
3.66
1.08
1.43
1.16
Basic average shares
-
4,026,000
4,003,000
3,981,000
3,957,600
Diluted average shares
-
4,084,000
4,052,000
4,030,000
4,012,800
EBITDA
-
8,805,000
8,750,000
8,484,000
10,129,000